173 related articles for article (PubMed ID: 30026381)
21. Utilization of genomic signatures to identify high-efficacy candidate drugs for chemorefractory endometrial cancers.
Kharma B; Baba T; Mandai M; Matsumura N; Murphy SK; Kang HS; Yamanoi K; Hamanishi J; Yamaguchi K; Yoshioka Y; Konishi I
Int J Cancer; 2013 Nov; 133(9):2234-44. PubMed ID: 23595697
[TBL] [Abstract][Full Text] [Related]
22. BMI1 is a therapeutic target in recurrent medulloblastoma.
Bakhshinyan D; Venugopal C; Adile AA; Garg N; Manoranjan B; Hallett R; Wang X; Mahendram S; Vora P; Vijayakumar T; Subapanditha M; Singh M; Kameda-Smith MM; Qazi M; McFarlane N; Mann A; Ajani OA; Yarascavitch B; Ramaswamy V; Farooq H; Morrissy S; Cao L; Sydorenko N; Baiazitov R; Du W; Sheedy J; Weetall M; Moon YC; Lee CS; Kwiecien JM; Delaney KH; Doble B; Cho YJ; Mitra S; Kaplan D; Taylor MD; Davis TW; Singh SK
Oncogene; 2019 Mar; 38(10):1702-1716. PubMed ID: 30348991
[TBL] [Abstract][Full Text] [Related]
23. BMI1 is expressed in canine osteosarcoma and contributes to cell growth and chemotherapy resistance.
Shahi MH; York D; Gandour-Edwards R; Withers SS; Holt R; Rebhun RB
PLoS One; 2015; 10(6):e0131006. PubMed ID: 26110620
[TBL] [Abstract][Full Text] [Related]
24. Silencing of Bmi-1 gene enhances chemotherapy sensitivity in human glioblastoma cells.
Hong Y; Shang C; Xue YX; Liu YH
Med Sci Monit; 2015 Apr; 21():1002-7. PubMed ID: 25858624
[TBL] [Abstract][Full Text] [Related]
25.
Altwerger G; Bonazzoli E; Bellone S; Egawa-Takata T; Menderes G; Pettinella F; Bianchi A; Riccio F; Feinberg J; Zammataro L; Han C; Yadav G; Dugan K; Morneault A; Ponte JF; Buza N; Hui P; Wong S; Litkouhi B; Ratner E; Silasi DA; Huang GS; Azodi M; Schwartz PE; Santin AD
Mol Cancer Ther; 2018 May; 17(5):1003-1011. PubMed ID: 29440294
[TBL] [Abstract][Full Text] [Related]
26. Bmi1 regulates self-renewal and epithelial to mesenchymal transition in breast cancer cells through Nanog.
Paranjape AN; Balaji SA; Mandal T; Krushik EV; Nagaraj P; Mukherjee G; Rangarajan A
BMC Cancer; 2014 Oct; 14():785. PubMed ID: 25348805
[TBL] [Abstract][Full Text] [Related]
27. Bmi‑1‑targeting suppresses osteosarcoma aggressiveness through the NF‑κB signaling pathway.
Liu J; Luo B; Zhao M
Mol Med Rep; 2017 Dec; 16(6):7949-7958. PubMed ID: 28983587
[TBL] [Abstract][Full Text] [Related]
28. Circular RNA BMI1 Serves as a Potential Target for Diagnosis and Treatment in Esophageal Cancer.
Zhao Q; Zhu X; Ke JM; Su XY; Yi J; Wu DL; Lin J; Deng ZQ
Technol Cancer Res Treat; 2021; 20():15330338211033075. PubMed ID: 34278876
[TBL] [Abstract][Full Text] [Related]
29. Targeting P16INK4A in uterine serous carcinoma through inhibition of histone demethylation.
Xiao Z; He Y; Liu C; Xiang L; Yi J; Wang M; Shen T; Shen L; Xue Y; Shi H; Liu P
Oncol Rep; 2019 May; 41(5):2667-2678. PubMed ID: 30896884
[TBL] [Abstract][Full Text] [Related]
30. Epigenetic Regulation of Bmi1 by Ubiquitination and Proteasomal Degradation Inhibit Bcl-2 in Acute Myeloid Leukemia.
Kushwaha AC; Mohanbhai SJ; Sardoiwala MN; Sood A; Karmakar S; Roy Choudhury S
ACS Appl Mater Interfaces; 2020 Jun; 12(23):25633-25644. PubMed ID: 32453568
[TBL] [Abstract][Full Text] [Related]
31. Bmi1 drives stem-like properties and is associated with migration, invasion, and poor prognosis in tongue squamous cell carcinoma.
He Q; Liu Z; Zhao T; Zhao L; Zhou X; Wang A
Int J Biol Sci; 2015; 11(1):1-10. PubMed ID: 25552924
[TBL] [Abstract][Full Text] [Related]
32. Aberrantly elevated Bmi1 promotes cervical cancer tumorigenicity and tumor sphere formation via enhanced transcriptional regulation of Sox2 genes.
Xu R; Chen L; Yang WT
Oncol Rep; 2019 Aug; 42(2):688-696. PubMed ID: 31173263
[TBL] [Abstract][Full Text] [Related]
33. The Role of Castration-Resistant Bmi1+Sox2+ Cells in Driving Recurrence in Prostate Cancer.
Yoo YA; Vatapalli R; Lysy B; Mok H; Desouki MM; Abdulkadir SA
J Natl Cancer Inst; 2019 Mar; 111(3):311-321. PubMed ID: 30312426
[TBL] [Abstract][Full Text] [Related]
34. Oncogenic roles of Bmi1 and its therapeutic inhibition by histone deacetylase inhibitor in tongue cancer.
Li Z; Wang Y; Yuan C; Zhu Y; Qiu J; Zhang W; Qi B; Wu H; Ye J; Jiang H; Yang J; Cheng J
Lab Invest; 2014 Dec; 94(12):1431-45. PubMed ID: 25286028
[TBL] [Abstract][Full Text] [Related]
35. Management Strategies for Recurrent Endometrial Cancer.
Connor EV; Rose PG
Expert Rev Anticancer Ther; 2018 Sep; 18(9):873-885. PubMed ID: 29972650
[TBL] [Abstract][Full Text] [Related]
36. Growth Hormone differentially modulates chemoresistance in human endometrial adenocarcinoma cell lines.
Gentilin E; Minoia M; Bondanelli M; Tagliati F; Degli Uberti EC; Zatelli MC
Endocrine; 2017 Jun; 56(3):621-632. PubMed ID: 27585662
[TBL] [Abstract][Full Text] [Related]
37. Co-delivery of Bmi1 small interfering RNA with ursolic acid by folate receptor-targeted cationic liposomes enhances anti-tumor activity of ursolic acid
Li W; Yan R; Liu Y; He C; Zhang X; Lu Y; Khan MW; Xu C; Yang T; Xiang G
Drug Deliv; 2019 Dec; 26(1):794-802. PubMed ID: 31366257
[TBL] [Abstract][Full Text] [Related]
38. Systemic therapy in metastatic or recurrent endometrial cancer.
Pectasides D; Pectasides E; Economopoulos T
Cancer Treat Rev; 2007 Apr; 33(2):177-90. PubMed ID: 17196749
[TBL] [Abstract][Full Text] [Related]
39. BMI1 activates P-glycoprotein via transcription repression of
Chen MK; Zhou JH; Wang P; Ye YL; Liu Y; Zhou JW; Chen ZJ; Yang JK; Liao DY; Liang ZJ; Xie X; Zhou QZ; Xue KY; Guo WB; Xia M; Bao JM; Yang C; Duan HF; Wang HY; Huang ZP; Qin ZK; Liu CD
Aging (Albany NY); 2021 Jul; 13(14):18310-18330. PubMed ID: 34270461
[TBL] [Abstract][Full Text] [Related]
40. Enhancing the therapeutic effect via elimination of hepatocellular carcinoma stem cells using Bmi1 siRNA delivered by cationic cisplatin nanocapsules.
Yang T; Chen Y; Zhao P; Xue H; You J; Li B; Liu Y; He C; Zhang X; Fan L; Lee RJ; Li L; Ma X; Xu C; Xiang G
Nanomedicine; 2018 Oct; 14(7):2009-2021. PubMed ID: 29842934
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
